Michael Shetzline's Insider Trades & SAST Disclosures
Michael Shetzline's most recent trade in Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A was a trade of 133,333 Class A Common Stock done . Disclosure was reported to the exchange on Feb. 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael Shetzline.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals I... | Michael Shetzline | SVP, CMO, Head-Res&Drug | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 133,333 | 595,276 (0%) | 0% | 0 | Class A Common Stock | |
| Ironwood Pharmaceuticals I... | Michael Shetzline | SVP, CMO, Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 1.76 per share. | 10 Feb 2025 | 41,269 | 554,007 (0%) | 0% | 1.8 | 72,633 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | SVP, CMO, Head-Res&Drug | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 48,224 | 461,943 (0%) | 0% | 0 | Class A Common Stock | |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 6.45 per share. | 20 May 2024 | 16,128 | 413,719 (0%) | 0% | 6.5 | 104,026 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 34,936 | 429,847 (0%) | 0% | 0 | Class A Common Stock | |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 34,936 | 0 | - | - | Performance-based Restricted Stock Unit | |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 54,427 | 394,911 (0%) | 0% | 0 | Class A Common Stock | |
| Ironwood Pharmaceuticals I... | Shetzline Michael | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 15.24 per share. | 12 Feb 2024 | 38,618 | 340,484 (0%) | 0% | 15.2 | 588,538 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 27,214 | 27,214 | - | - | Performance-based Restricted Stock Unit | |
| Ironwood Pharmaceuticals I... | Shetzline Michael | CMO,SVP,Head-Res&Drug | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2024 | 57,971 | 379,102 (0%) | 0% | 0 | Class A Common Stock | |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 10.12 per share. | 22 May 2023 | 10,324 | 321,131 (0%) | 0% | 10.1 | 104,479 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 69,869 | 331,455 (0%) | 0% | 0 | Class A Common Stock | |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 34,935 | 34,935 | - | - | Performance-based Restricted Stock Units | |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 11.31 per share. | 27 Feb 2023 | 7,438 | 264,002 (0%) | 0% | 11.3 | 84,124 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 11.41 per share. | 27 Feb 2023 | 7,146 | 273,762 (0%) | 0% | 11.4 | 81,536 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 11.31 per share. | 27 Feb 2023 | 2,416 | 261,586 (0%) | 0% | 11.3 | 27,325 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 11.41 per share. | 27 Feb 2023 | 2,322 | 271,440 (0%) | 0% | 11.4 | 26,494 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2023 | 14,663 | 280,908 (0%) | 0% | 0 | Class A Common Stock | |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 11.50 per share. | 23 May 2022 | 7,453 | 266,245 (0%) | 0% | 11.5 | 85,710 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 11.50 per share. | 23 May 2022 | 3,130 | 273,698 (0%) | 0% | 11.5 | 35,995 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 10.77 per share. | 28 Feb 2022 | 5,161 | 203,548 (0%) | 0% | 10.8 | 55,584 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 10.77 per share. | 28 Feb 2022 | 4,364 | 195,380 (0%) | 0% | 10.8 | 47,000 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 10.77 per share. | 28 Feb 2022 | 3,804 | 199,744 (0%) | 0% | 10.8 | 40,969 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 10.77 per share. | 28 Feb 2022 | 2,911 | 208,709 (0%) | 0% | 10.8 | 31,351 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 10.77 per share. | 28 Feb 2022 | 1,367 | 211,620 (0%) | 0% | 10.8 | 14,723 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 29,326 | 212,987 (0%) | 0% | 0 | Class A Common Stock | |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO,SVP,Head-Res&Drug | Sale of securities on an exchange or to another person at price $ 11.58 per share. | 23 Nov 2021 | 13,776 | 183,661 (0%) | 0% | 11.6 | 159,526 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO, SVP & Head of Drug Devt. | Sale of securities on an exchange or to another person at price $ 12.25 per share. | 24 May 2021 | 2,077 | 197,437 (0%) | 0% | 12.2 | 25,443 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO, SVP & Head of Drug Devt. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2021 | 38,655 | 199,514 (0%) | 0% | 0 | Class A Common Stock | |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO, SVP & Head of Drug Devt. | Sale of securities on an exchange or to another person at price $ 9.11 per share. | 26 Feb 2021 | 3,041 | 160,859 (0%) | 0% | 9.1 | 27,704 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO, SVP & Head of Drug Devt. | Sale of securities on an exchange or to another person at price $ 9.11 per share. | 26 Feb 2021 | 1,398 | 163,900 (0%) | 0% | 9.1 | 12,736 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO, SVP & Head of Drug Devt. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 58,252 | 165,298 (0%) | 0% | 0 | Class A Common Stock | |
| Ironwood Pharmaceuticals I... | Michael Shetzline | CMO, SVP & Head of Drug Devt. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 20,740 | 107,046 (0%) | 0% | 0 | Class A Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges